{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T23:39:31Z","timestamp":1792366771450,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373449"],"award-info":[{"award-number":["82373449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77697-5","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:43:45Z","timestamp":1789620225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A lipoprotein-biomimetic nanoplatform for oncogenic KRAS mutation-specific lysosome-targeting protein degradation"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-4877","authenticated-orcid":false,"given":"Hang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8114-6061","authenticated-orcid":false,"given":"Jiafeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4960-5847","authenticated-orcid":false,"given":"Xiangrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuansheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0120-2371","authenticated-orcid":false,"given":"Qian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6252-0154","authenticated-orcid":false,"given":"Quan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-3717","authenticated-orcid":false,"given":"Kefeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"77697_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","volume":"21","author":"B Dale","year":"2021","unstructured":"Dale, B. et al. Advancing targeted protein degradation for cancer therapy. Nat. Rev. Cancer 21, 638\u2013654 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"77697_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","volume":"584","author":"SM Banik","year":"2020","unstructured":"Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291\u2013297 (2020).","journal-title":"Nature"},{"key":"77697_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41586-024-07947-3","volume":"638","author":"D Zhang","year":"2025","unstructured":"Zhang, D. et al. Transferrin receptor targeting chimeras for membrane protein degradation. Nature 638, 787\u2013795 (2025).","journal-title":"Nature"},{"key":"77697_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","volume":"41","author":"K Pance","year":"2023","unstructured":"Pance, K. et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat. Biotechnol. 41, 273\u2013281 (2023).","journal-title":"Nat. Biotechnol."},{"key":"77697_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.addr.2019.04.008","volume":"143","author":"ND Donahue","year":"2019","unstructured":"Donahue, N. D., Acar, H. & Wilhelm, S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv. Drug Deliv. Rev. 143, 68\u201396 (2019).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"77697_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","volume":"16","author":"JJ Rennick","year":"2021","unstructured":"Rennick, J. J., Johnston, A. P. R. & Parton, R. G. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat. Nanotechnol. 16, 266\u2013276 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"77697_CR7","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1039\/D0CS01127D","volume":"50","author":"M Sousa de Almeida","year":"2021","unstructured":"Sousa de Almeida, M. et al. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem. Soc. Rev. 50, 5397\u20135434 (2021).","journal-title":"Chem. Soc. Rev."},{"key":"77697_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51720-z","volume":"15","author":"S Yao","year":"2024","unstructured":"Yao, S. et al. A plug-and-play monofunctional platform for targeted degradation of extracellular proteins and vesicles. Nat. Commun. 15, 7237 (2024).","journal-title":"Nat. Commun."},{"key":"77697_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41565-024-01801-3","volume":"20","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Targeted protein degradation via cellular trafficking of nanoparticles. Nat. Nanotechnol. 20, 296\u2013302 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"77697_CR10","volume":"10","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. Nano-LYTACs for degradation of membrane proteins and inhibition of CD24\/Siglec-10 signaling pathway. Adv. Sci. Weinh. Baden.-Wurtt. Ger. 10, e2300288 (2023).","journal-title":"Adv. Sci. Weinh. Baden.-Wurtt. Ger."},{"key":"77697_CR11","doi-asserted-by":"publisher","first-page":"36301","DOI":"10.1021\/jacs.5c09630","volume":"147","author":"Z Yang","year":"2025","unstructured":"Yang, Z. et al. Cell-selective targeting chimeras (SelecTACB) for membrane protein degradation on B Cells. J. Am. Chem. Soc. 147, 36301\u201336309 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"77697_CR12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","volume":"17","author":"G Ahn","year":"2021","unstructured":"Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937\u2013946 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"77697_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"77697_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","volume":"20","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2020","unstructured":"Mart\u00ednez-Jim\u00e9nez, F. et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 20, 555\u2013572 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"77697_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/cac2.12377","volume":"43","author":"H Yang","year":"2023","unstructured":"Yang, H. et al. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Cancer Commun. 43, 42\u201374 (2023).","journal-title":"Cancer Commun."},{"key":"77697_CR16","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio, V. et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 10, 1129\u20131139 (2020).","journal-title":"Cancer Discov."},{"key":"77697_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","volume":"13","author":"R Yaeger","year":"2023","unstructured":"Yaeger, R. et al. Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer. Cancer Discov. 13, 41\u201355 (2023).","journal-title":"Cancer Discov."},{"key":"77697_CR18","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"77697_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/2159-8290.CD-20-1616","volume":"11","author":"NS Akhave","year":"2021","unstructured":"Akhave, N. S., Biter, A. B. & Hong, D. S. Mechanisms of resistance to KRASG12C-targeted therapy. Cancer Discov. 11, 1345\u20131352 (2021).","journal-title":"Cancer Discov."},{"key":"77697_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho, M. A. et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083\u20131099.e6 (2017).","journal-title":"Immunity"},{"key":"77697_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh, S., Gro\u00df, O., Brummer, T. & Zeiser, R. Immune modulatory effects of oncogenic KRAS in cancer. Nat. Commun. 11, 5439 (2020).","journal-title":"Nat. Commun."},{"key":"77697_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature12138","volume":"497","author":"C Commisso","year":"2013","unstructured":"Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in ras-transformed cells. Nature 497, 633\u2013637 (2013).","journal-title":"Nature"},{"key":"77697_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1101\/gad.2016311","volume":"25","author":"JY Guo","year":"2011","unstructured":"Guo, J. Y. et al. Activated ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 25, 460\u2013470 (2011).","journal-title":"Genes Dev."},{"key":"77697_CR24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-019-0368-8","volume":"25","author":"KL Bryant","year":"2019","unstructured":"Bryant, K. L. et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat. Med. 25, 628\u2013640 (2019).","journal-title":"Nat. Med."},{"key":"77697_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102307","volume":"56","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. Impact of protein corona and PEGylation on the accumulation and efficacy of lysosome-disrupting lipid nanoparticles in KRAS-mutated cancer. Nano Today 56, 102307 (2024).","journal-title":"Nano Today"},{"key":"77697_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15144","volume":"8","author":"J-L Huang","year":"2017","unstructured":"Huang, J.-L. et al. Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis. Nat. Commun. 8, 15144 (2017).","journal-title":"Nat. Commun."},{"key":"77697_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201900631","volume":"15","author":"Y Pei","year":"2019","unstructured":"Pei, Y. et al. Sequential targeting TGF-\u03b2 signaling and KRAS mutation increases therapeutic efficacy in pancreatic cancer. Small 15, 1900631 (2019).","journal-title":"Small"},{"key":"77697_CR28","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/celldisc.2017.4","volume":"3","author":"F Zhang","year":"2017","unstructured":"Zhang, F. et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 3, 17004 (2017).","journal-title":"Cell Discov."},{"key":"77697_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/2326-6066.CIR-15-0176","volume":"4","author":"AJ Vandeveer","year":"2016","unstructured":"Vandeveer, A. J. et al. Systemic Immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor. Cancer Immunol. Res. 4, 452\u2013462 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"77697_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"},{"key":"77697_CR31","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-17-0483","volume":"23","author":"C Xu","year":"2017","unstructured":"Xu, C. et al. Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 23, 5869\u20135880 (2017).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"77697_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161660","volume":"134","author":"E Stefanidis","year":"2024","unstructured":"Stefanidis, E. et al. Combining SiRP\u03b1 decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells. J. Clin. Invest. 134, e161660 (2024).","journal-title":"J. Clin. Invest."},{"key":"77697_CR33","doi-asserted-by":"publisher","unstructured":"Jun, S. et al. Discovery of novel triple A1\/A2A\/A2B adenosine receptor antagonists for cancer immunotherapy. J. Med. Chem https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02009 (2025).","DOI":"10.1021\/acs.jmedchem.5c02009"},{"key":"77697_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"77697_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies, A., Zehn, D. & Utzschneider, D. T. Precursor exhausted T cells: key to successful immunotherapy? Nat. Rev. Immunol. 20, 128\u2013136 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"77697_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.matbio.2013.10.004","volume":"35","author":"HC Christianson","year":"2014","unstructured":"Christianson, H. C. & Belting, M. Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biol. J. Int. Soc. Matrix Biol. 35, 51\u201355 (2014).","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"77697_CR37","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1016\/j.apsb.2022.04.013","volume":"12","author":"Y Li","year":"2022","unstructured":"Li, Y., Ye, Z., Yang, H. & Xu, Q. Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs. Acta Pharm. Sin. B. 12, 2624\u20132639 (2022).","journal-title":"Acta Pharm. Sin. B."},{"key":"77697_CR38","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"77697_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45422-9","volume":"15","author":"L Xue","year":"2024","unstructured":"Xue, L. et al. High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models. Nat. Commun. 15, 1884 (2024).","journal-title":"Nat. Commun."},{"key":"77697_CR40","doi-asserted-by":"publisher","unstructured":"Witten, J. et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat. Biotechnol https:\/\/doi.org\/10.1038\/s41587-024-02490-y (2024).","DOI":"10.1038\/s41587-024-02490-y"},{"key":"77697_CR41","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41563-024-01867-3","volume":"23","author":"B Li","year":"2024","unstructured":"Li, B. et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat. Mater. 23, 1002\u20131008 (2024).","journal-title":"Nat. Mater."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77697-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77697-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77697-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:47:11Z","timestamp":1792363631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77697-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77697"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77697-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10907"}}